Vitamin K Deficiency Bleeding (VKDB) in Infants – Diagnosis, Risk Factors, and Prevention
Definition & Diagnostic Criteria
- VKDB is a serious, preventable bleeding disorder in infants caused by insufficient vitamin K‑dependent clotting factors (II, VII, IX, X) and can occur even when an underlying bleeding disorder is present, making universal prophylaxis essential. [@1]
- Diagnosis is suggested by a prolonged prothrombin time (PT) – and occasionally an age‑appropriate activated partial thromboplastin time (aPTT) – in the newborn. [@1]
- A rapid normalization of PT within 2–4 hours after a single dose of vitamin K confirms the diagnosis. [@4]
- Measurement of PIVKA‑II (proteins induced by vitamin K absence) can confirm VKDB in infants who have already received vitamin K therapy. [@1]
Clinical Presentation by Age
- Early VKDB (≤ 24 h) is rare and is frequently linked to maternal medications that interfere with vitamin K metabolism. [@4]
- Classic VKDB (days 1–7) is the most common form; typical bleeding sites include circumcision wounds and the umbilical stump. [@1]
- Late VKDB (2 weeks–6 months) is the most dangerous, with a high risk of intracranial hemorrhage (ICH). [@6]
Specific Bleeding Manifestations
- Skin or mucosal bleeding (e.g., petechiae, epistaxis). [@5]
- Bleeding from circumcision sites. [@3]
- Generalized ecchymoses (widespread bruising). [@3]
- Large intramuscular hemorrhages. [@5]
- Intracranial hemorrhage – the most devastating complication. [@6]
- Gastrointestinal bleeding. [@5]
High‑Risk Infants
- Exclusively breast‑fed infants (breast milk contains low vitamin K). [@4]
- Infants whose mothers used anticonvulsants, anticoagulants, or antituberculosis drugs during pregnancy. [@4]
- Infants with cholestasis, malabsorption syndromes, cystic fibrosis, or other disorders impairing fat absorption. [@4]
- Infants with α‑1‑antitrypsin deficiency. [@7]
- Infants who did not receive vitamin K prophylaxis at birth. [@5]
Differential Diagnosis
- VKDB must be distinguished from immune thrombocytopenia (ITP) by performing a platelet count. [@1]
- It also needs to be differentiated from hemophilia and other factor deficiencies, platelet function disorders, and von Willebrand disease, all of which present with normal vitamin K‑dependent factor levels. [@1]
Prevention (Prophylaxis)
- Universal prophylaxis: All newborns should receive vitamin K at birth. [@4]
- Intramuscular (IM) route (preferred) – a single dose of 0.5–1.0 mg vitamin K₁ administered within the first hour of life is the most effective strategy for preventing early, classic, and late VKDB. [@5]
- Oral route (alternative when IM is refused) – either 2 mg at birth, 2 mg at 4–6 days, and 2 mg at 4–6 weeks, or 2 mg at birth followed by weekly 1 mg doses for three months. Oral regimens are less effective and require strict parental compliance. [@4]
- Preterm infants receiving parenteral nutrition – 10 µg/kg/day of vitamin K is recommended. [@4]
- Oral prophylaxis is not appropriate for preterm infants, those with cholestasis, malabsorption, critical illness, or maternal medication interference. [ignore ref – omitted]
Warning Signs Requiring Immediate Evaluation
- Prolonged jaundice beyond the expected age‑appropriate period. [@7]
- Failure to thrive. [@5]
- Any “warning bleed” (minor bleeding episodes) in an at‑risk infant. [@5]
- Easy bruising in an exclusively breast‑fed infant who has not received prophylaxis. [@4]
Monitoring Considerations
- PIVKA‑II is the preferred biomarker for assessing vitamin K status in high‑risk infants when the assay is available. [@4]
- Conventional coagulation tests (PT, aPTT) can be used for initial screening but are not specific for VKDB. [@4]
- Routine measurement of serum vitamin K concentrations is not recommended. [@4]